Treatment of (complex) PTSD symptoms in patients diagnosed with PTSD. Mental and Behavioural Disorders Post-traumatic stress disorder
Conditions
Interventions
Participants are randomly assigned to one of three treatment conditions using an online tool (sealedenvelope.com). There are two intervention groups and one control group. Participants in one interven
Sponsors
Utrecht University
Eligibility
Sex/Gender
All
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 1. A primary diagnosis of PTSD, administered with the CAPS-5. 2. A minimum age of 18 years old. 3. An estimated IQ of above 80. 4. Sufficient understanding of the Dutch language.
Exclusion criteria
Exclusion criteria: 1. The use of benzodiazepines is a contra-indication for treatment and will be tapered as much as possible before participation. Participants are prohibited to use benzodiazepines 24 hours before or after each treatment sessions. 2. The use of drugs during treatment. 3. The use of alcohol is allowed, with the exception of 24 hours before and after a treatment sessions. For the rest of the week, participants are allowed a maximum of 2 units. 4. Acute suicidality 5. Change in medication during the study or six weeks prior to participation, with the exception of tapering benzodiazepines.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. PTSD symptoms measured with the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) at baseline, post-treatment (4 weeks after the last treatment session) and follow-up (12 weeks after the last treamtent session) and the PTSD symptom Checklist for DSM-5 (PCL-5) at baseline, weekly during treatment phase and bi-weekly after the last treatment session until 12 week follow-up. 2. PTSD diagnosis measured with the CAPS-5 at baseline, post-treatment and follow-up. 3. Complex PTSD symptoms measured with the International Trauma Questionnaire (ITQ) at baseline, post-treatment and follow-up. 4. Complex PTSD diagnosis measured with the ITQ at baseline, post-treatment and follow-up. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Depressive symptoms measured with the Beck Depression Inventory-II (BDI-II) at baseline, weekly during the treatment phase and bi-weekly after the last treatment session until 12-week follow-up. 2. Dissociative symptoms measured with the Dissociative Experiences Scale (DES) at baseline, post-treatment and follow-up. 3. General psychiatric symptoms measured with the Brief Symptom Inventory (BSI) at baseline, weekly during the treatment phase and bi-weekly after the last treatment session until 12-week follow-up. 4. Experiential avoidance measured with the Acceptance and Action Questionnaire-II (AAQ-II) at baseline, weekly during the treatment phase and bi-weekly after the last treatment session until 12-week follow-up. 5. Treatment acceptability measured with four questions that measure several facets which could be grouped under treatment acceptability at the second week of treatment and two weeks after the last treatment session. 6. Treatment efficiency measured with intervention time needed to achieve a Subjective Units of Disturbance (SUD) score of 0 and amount of sessions needed to achieve clinically significant change and a cut-off score on the PCL-5. Intervention time and SUD scores will be measured at treatment sessions and the PCL-5 will be measured weekly during the treatment phase. | — |
Countries
Netherlands
Contacts
Public ContactValentijn Alting van Geusau
Outcome results
None listed